FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN RENEEICIAL	OWNERSH

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Cooper Laurence James Neil</u>					2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ZIOP]								(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	(Last) (First) (Middle) C/O ZIOPHARM ONCOLOGY, INC. ONE FIRST AVENUE, PARRIS BLDG. 34					3. Date of Earliest Transaction (Month/Day/Year) 01/06/2019								X	below)	give title	utive	Other (s below) Officer	pecify
(Street) BOSTO	N M		02129 (Zip)		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Ind Line)	′							
		Та	ble I - No	n-Deri	ivativ	ve Se	curities	s Ac	quired,	Dis	posed o	of, or	Bene	eficially	Owned				
Date		Date	saction //Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disp Code (Instr.			curities Acquired (A) o osed Of (D) (Instr. 3, 4			Beneficia Owned Fo	s lly ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)					
Common Stock 01/06			06/20	2019		A		337,266 ⁽¹⁾ A \$		\$0.00	1,518,075			D					
Common Stock 01/0			06/201	/2019		A		446,428 ⁽²⁾ A \$		\$0.00	1,964,503			D					
Common Stock 01/06			06/20	/2019		F		165,178 ⁽³⁾ D \$		\$2.24	1,799,325			D					
			Table II -								osed of, onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code (I			Derivative		6. Date Exercisa Expiration Date (Month/Day/Yea			of Sec Under Deriva	7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	Owner Form Direct or Ind (I) (In:	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				С	Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	0	Amount or lumber of Shares		Transaction(s) (Instr. 4)		'	
Employee Stock Option (right to buy)	\$2.24	01/06/2019			A		531,813		(4)		01/06/2029	Comn		531,813	\$0.00	531,81	13	D	

Explanation of Responses:

- 1. 112,422 shares shall vest on each of 12/31/2019, 12/31/2020 and 12/31/2021.
- 2. Pursuant to the Issuer's option plan, the Reporting Person elected to receive fully vested shares of Common Stock in lieu of a cash bonus.
- 3. Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grant.
- 4. 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018.

Remarks:

/s/ Kevin Lafond, Attorney-in-Fact 01/08/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.